William Blair analyst Myles Minter has reiterated their bullish stance on ARCT stock, giving a Buy rating on August 6.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Myles Minter has given his Buy rating due to a combination of factors that highlight Arcturus Therapeutics’ promising developments and strategic advancements. The company is progressing with its ARCT-032 program, aimed at treating cystic fibrosis patients who do not respond well to existing CFTR modulator therapies. The interim data from their Phase II trial, which is expected in September, will provide insights into the efficacy and safety of the treatment, with positive results potentially leading to further advancement in their clinical trials.
Additionally, Arcturus is making strides with its COVID-19 sa-mRNA vaccine, Kostaive, which has already generated significant collaboration revenue. The company’s innovative approach, leveraging differentiated LNP chemistry and mRNA purification platforms, underpins its confidence in the safety and effectiveness of its pipeline. These factors, combined with anticipated regulatory discussions and potential Phase III trial initiation in 2026, contribute to Minter’s optimistic outlook and Buy rating for Arcturus Therapeutics.
In another report released on August 6, Canaccord Genuity also maintained a Buy rating on the stock with a $66.00 price target.